Artificial intelligence (AI) continues to disrupt existing paradigms in drug development, with early adopters experiencing both the benefits and challenges of this innovative technology. With that in ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

Since 2008, PCM Trials has led the way in mobile research. Our Certified Mobile Research Nurses (CMRNs) are driving the shift to patient-centric, decentralized clinical trials, giving individuals the ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

Revolo Biotherapeutics’ pipeline is focusing on creating a commercially viable subcutaneous dosage form for its lead candidate while working on a sublingual solution that is even more patient friendly ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski explain the importance of transparency and collaboration when encountering manufacturing speed bumps.

In anticipation of ISCT 2024 in Vancouver, Canada, Dr. Bruce Levine is back on Cell & Gene: The Podcast to share information about the event as well as his expertise on the future of CAR-T therapy for ...

Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) ...

Aron Knickerbocker leverages his Big Pharma credentials to launch successful biotech startups, including his most recent venture, Aulos, which uses AI to accelerate drug development.

In this Business Solutions podcast, John Bodrozic, cofounder of software developer HomeZada, discusses some of the challenges software developer companies face when raising capital. While bootstrap ...

Eamonn Hobbs brings decades of drug device innovation experience to helm Syncromune's promising Sync-T solid tumor therapeutic platform.

In this presentation, Thomas Gervais, Ph.D., Head of Manufacturing Sciences and Technology, Samsung Biologics, discusses key considerations and challenges in implementing N-1 perfusion technology as ...